Genetic Testing in the Management of Adult CKD
Authors:
- Fouad T. ChebibFCFouad T. Chebib
- Xiangling WangXWXiangling Wang
- Suneel M. UdaniSUSuneel M. Udani
- Maggie WestemeyerMWMaggie Westemeyer
- Michelle S. BloomMBMichelle S. Bloom
- Hila Milo RasoulyHRHila Milo Rasouly
- Mohammad R. MizaniMMMohammad R. Mizani
- Neville R. DossabhoyNDNeville R. Dossabhoy
- Arman FaravardehAFArman Faravardeh
Open Access
- 29 October 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (4) , 777-789
Abstract
Key Points: Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy. Background: CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing. Methods: The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point. Results: In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding. Conclusions: Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.Keywords
Funding Information
- Natera
This publication has 49 references indexed in Scilit:
- Genetic evaluation of living kidney donor candidates: A review and recommendations for best practicesAmerican Journal of Transplantation, 2023
- UMOD and you! Explaining a rare disease diagnosisJournal of Rare Diseases, 2022
- Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2022
- The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene ProjectJournal Of Nephrology, 2022
- Genetic testing for kidney disease of unknown etiologyKidney International, 2020
- Autosomal Dominant Tubulointerstitial Kidney Disease—Uromodulin Misclassified as Focal Segmental Glomerulosclerosis or Hereditary Glomerular DiseaseKidney International Reports, 2020
- Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal diseaseKidney International, 2019
- Monogenic causes of chronic kidney disease in adultsKidney International, 2019
- Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disordersKidney International, 2017
- Bartter's and Gitelman's syndromes: their relationship to the actions of loop and thiazide diureticsCurrent Opinion in Pharmacology, 2006